GSK to launch Phase 3 test of mRNA flu vaccine with newer formulation

Phase 3mRNA flu vaccinePositive

AI Analysis

Summary

GSK announced initiation of a Phase 3 trial for its mRNA seasonal flu vaccine following Phase 2 data showing superior immune responses compared to traditional vaccines.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Phase 2 showed higher immune responses than traditional vaccines

Importance:7/10

Sentiment:

0.70

mRNAinfluenzavaccinePhase 3immunogenicity

Related Companies

$GSK

Read the original article

Published by Endpoints News on September 1, 2026 2:40 PM

Read Original